Recon: J&J reports lung cancer therapy significantly prolonged survival in study; Stryker to buy Inari Medical for $4.9B

• Generic GLP-1 drugs could help Medicare drive a harder bargain for Ozempic and Wegovy (STAT)
• Wegovy and Zepbound tipped to fuel $20B boom in heart failure market (Fierce Pharma)
• Johnson & Johnson says its lung cancer drug significantly extended survival (STAT) (Reuters)
• These common medications could be releasing ‘forever chemicals’ into the environment (The Washington Post)
• Google’s secretive anti-aging company Calico finally released data. Its drug failed (STAT)
• After tough year, Moderna CEO confronts challenges for RSV, COVID businesses in shareholder letter (Fierce Pharma)
• Device maker Stryker strikes $4.9 billion deal for Inari Medical (Reuters)
• AbbVie cuts 2024 profit forecast on acquisition expenses (Reuters)

• Anthem Biosciences eyes $397M public offering in India (Endpoints)
• France identifies first case of new mpox variant, AFP reports (Reuters)
• Medtechs Ponder Significance Of UK’s Elective Reform Plan (MedTech Insight)
• China Greenlights First Stem Cell Therapy On Mixed Clinical Findings (Pink Sheet)
• Japan’s 2025 ‘Off-Year’ Price Cut Stirs Deeper Concerns (Pink Sheet)
• Spanish Health Ministry Targets Efficiency With New Medicine Pricing Rules (Pink Sheet)
• Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty (BioSpace)
• Bird flu risk remains low after first US death, WHO says (Reuters)

• Can an epilepsy drug do more than reduce seizures? (STAT)
• Four years after AlphaFold’s AI ‘solved’ protein structure, a fierce competition lives on (STAT)
• Metsera’s long-acting GLP-1 looks competitive in Phase 2 obesity study (Endpoints)
• Immuneering touts positive pancreatic cancer data for MEK inhibitor (Endpoints)
• Vertex signs in vivo gene editing delivery pact for sickle cell and thalassemia as it looks beyond Casgevy (Endpoints)
• BWX Technologies to buy Canadian isotope maker for $525M (Endpoints)
• Pfizer extends AI drug discovery pact with PostEra, adding ADCs to deal (Endpoints)
• Forbion-backed cardio biotech rebrands to RyCarma with Phase 2 plans (Endpoints)
• Avenzo picks up another ADC, this time with multi-partnered DualityBio (Endpoints)
• XyloCor raises $67.5M Series B, updates pivotal gene therapy trial plans (Endpoints)
• Bausch + Lomb re-ups 'Faces of Glaucoma' campaign to raise awareness of the eye disease (Fierce Pharma)
• With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi (Fierce Pharma)
• Klick Health swoops in to acquire life sci market access agency Peregrine (Fierce Pharma)

• Wearable maker ActiGraph acquires assets from Biofourmis to boost clinical trial offerings (STAT)
• Philips sells small chipmaking subsidiary, Telegraaf reports (Reuters)
• Outset Medical to pay down debt after raising nearly $300M (MedTech Dive)

• The long history of distrust for American insurance companies (STAT)
• AI Adoption In Pathology Is Lagging: Funding And Clinical Standardization Needed (MedTech Insight)